IDEAS home Printed from
MyIDEAS: Login to save this article or follow this journal

Committing to Vaccine R&D: A Global Science Policy Priority/Comprometerse en la investigación y desarrollo de vacunas: una prioridad de la política científica global



    (Consiglio Nazionale delle Ricerche and London School of Economics and Political Science. Centre for the Study of Global Governance. Via dei Taurini, 19 00185 Roma. Houghton Street, London W2A 2AE; Telf.: +39-0649937838 – Fax +39-064463836)



    (Consiglio Nazionale delle Ricerche and London School of Economics and Political Science. Centre for the Study of Global Governance.Telf.: +44(0)20 7955 7434 – Fax +44(0)2079557591.)

Registered author(s):

    The amount of vaccine R&D performed, especially geared towards health issues affecting the developing world, is exceptionally undersized. Despite immunisation representing the most effective tool for achieving disease eradication, and the general consensus being optimistic about the development of a vaccine capable of fighting AIDS, Malaria and Tuberculosis, neither private nor public entities are investing sufficiently in the field. Reasons can be associated both with a lack of market incentives as well as with the low priority that these diseases set on Western political agendas. Though, seen through the Global Public Good lenses, it appears in the interest of high-income countries, their governments in primis, to invest public resources – financial and infra-structural – in vaccine R&D for global pandemics, as well as managing international cooperation through a global fund. The paper reviews a number of proposals put forward in the existing literature and offers a range of policy options. La cuantía invertida en I+D en vacunas, especialmente dirigida a cuestiones de salud que afectan al mundo en desarrollo, es excepcionalmente insuficiente. A pesar de que la inmunización representa el instrumento más efectivo para lograr la erradicación de enfermedades, y de que el consenso general es optimista sobre el desarrollo de una vacuna capaz de luchar contra el SIDA, la malaria y la tuberculosis, ni las entidades públicas ni las privadas están invirtiendo lo suficiente en este campo. Las razones de ello pueden asociarse tanto con una falta de incentivos de mercado como también con la baja prioridad que esas enfermedades tienen en las agendas políticas de Occidente. Si bien, visto desde la óptica de los Bienes Públicos Globales, parece que sería del interés de los países de rentas altas, e in primis de sus Gobiernos, el invertir recursos públicos – financieros y de infraestructura – en I+D en vacunas para las pandemias globales, así como gestionar la cooperación internacional por medio de un fondo global. Este trabajo revisa un conjunto de propuestas recogidas en la bibliografía existente, ofreciendo un conjunto de opciones de política al respecto.

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

    File URL:
    Download Restriction: Access to full text is restricted to subscribers.

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Article provided by Estudios de Economía Aplicada in its journal Estudios de Economía Aplicada.

    Volume (Year): 22 (2004)
    Issue (Month): (Agosto)
    Pages: 251-271

    in new window

    Handle: RePEc:lrk:eeaart:22_2_6
    Contact details of provider: Postal: Beatriz Rodríguez Prado. Facultad de CC.EE. y EE. Avda. Valle del Esgueva. Valladolid 47011 SPAIN
    Phone: (34) 983 423320
    Fax: (34) 983 184568
    Web page:

    More information through EDIRC

    Order Information: Web: Email:

    References listed on IDEAS
    Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

    as in new window
    1. Kenneth Arrow, 1962. "Economic Welfare and the Allocation of Resources for Invention," NBER Chapters, in: The Rate and Direction of Inventive Activity: Economic and Social Factors, pages 609-626 National Bureau of Economic Research, Inc.
    2. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
    3. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
    4. Mazzoleni, Roberto & Nelson, Richard R., 1998. "The benefits and costs of strong patent protection: a contribution to the current debate," Research Policy, Elsevier, vol. 27(3), pages 273-284, July.
    5. Frank, Richard G., 2003. "New estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 325-330, March.
    Full references (including those not matched with items on IDEAS)

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    When requesting a correction, please mention this item's handle: RePEc:lrk:eeaart:22_2_6. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Beatriz Rodríguez Prado)

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.